Thalidomide for the Treatment of Low Risk Myelodysplasia

We conducted a phase II trial of thalidomide in patients with low risk MDS issued from the GFM. 82 patients were included from january 2003 to june 2004: 38 RA, 19 RARS, 21 RAEB

Saved in:
Bibliographic Details
Published in:Blood 2004-11, Vol.104 (11), p.1438-1438
Main Authors: Bouscary, D., Quarre, M.C., Vassilief, D., Rouzy, O. Beyne, Aouba, A., Berthou, C., Gardembas, C., Sanhes, L., Guerci, A., Mahe, B., Stamatoullas, A., Bauduer, F., Sotto, J.J., Legros, L., Vaultier, S., Fenaux, P., Dreyfus, F.
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We conducted a phase II trial of thalidomide in patients with low risk MDS issued from the GFM. 82 patients were included from january 2003 to june 2004: 38 RA, 19 RARS, 21 RAEB
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V104.11.1438.1438